

Extra-intestinal malignancies in inflammatory bowel disease
Pathogenesis Scientific Workshop (III)

Journal of Crohn's and Colitis

8, 31-44

DOI: [10.1016/j.crohns.2013.04.006](https://doi.org/10.1016/j.crohns.2013.04.006)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Colimumab for the treatment of ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 53.	1.0	22
2	Previous Cancer and/or Lymphoma in Patients with Refractory IBD - Con: Anti-TNF or Conventional Immunosuppressive Treatment. <i>Digestive Diseases</i> , 2014, 32, 122-127.	0.8	9
3	Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 338-353.	1.9	78
4	Previous Cancer and/or Lymphoma in Patients with Refractory IBD - Pro: Anti-TNF or Immunosuppressive Treatment. <i>Digestive Diseases</i> , 2014, 32, 116-121.	0.8	8
5	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 447-458.	1.9	144
6	Treatment algorithms in Crohn's " Up, down or something else?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 473-483.	1.0	29
7	Oxidative Stress and DNA Damage. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	100
8	Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 21.	1.4	160
9	Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1847-1853.	0.9	77
10	Cancer and Immunomodulators in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 674-698.	0.9	55
11	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 391-405.	1.9	99
12	Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. <i>Drug Development Research</i> , 2015, 76, 419-427.	1.4	48
14	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 731-746.	1.4	11
15	Malignancies in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 81-89.	0.6	14
16	Ionizing radiation exposure in patients with inflammatory bowel disease: Are we overexposing our patients?. <i>Journal of Digestive Diseases</i> , 2015, 16, 83-89.	0.7	37
17	The epidemiology of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 942-951.	0.6	272
18	Epstein-Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403.	0.6	70
19	Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 871-883.	1.8	11

#	ARTICLE	IF	CITATIONS
20	Incidence, Management, and Course of Cancer in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 326-333.	0.6	38
21	Monitoring for Extra-Intestinal Cancers in IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 42.	1.1	17
22	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1595-1602.	1.0	5
23	Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3399-3407.	1.1	25
24	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 945-965.	0.6	328
25	The role and advances of immunomodulator therapy for inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 177-189.	1.4	27
26	Advances in the development of new biologics in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2016, 29, 243-8.	0.4	41
27	Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-18.	0.7	19
28	CT and MRI of Rare Extraintestinal Manifestations of Inflammatory Bowel Disease in Children and Adolescents. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, e1-9.	0.9	5
29	Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. <i>International Journal of Cancer</i> , 2016, 139, 1270-1280.	2.3	65
30	Care of inflammatory bowel disease patients in remission. <i>Gastroenterology Report</i> , 2016, 4, gow032.	0.6	15
31	Practical Approaches to “Top-Down” Therapies for Crohn’s Disease. <i>Current Gastroenterology Reports</i> , 2016, 18, 35.	1.1	11
32	A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2016, 51, 1050-1062.	2.3	30
33	Crohn’s disease and skin. <i>United European Gastroenterology Journal</i> , 2016, 4, 165-171.	1.6	10
34	DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1316-1323.	0.6	46
35	Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 12-13.	1.4	2
36	Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw193.	0.6	28
37	Anti-TNF therapy for chronic inflammatory disease in kidney transplant recipients. <i>Medicine (United Tj ETQq1 1 0,784314 rgBT /Over</i>	0.4	26

#	ARTICLE	IF	CITATIONS
38	Lactobacillus plantarum ZS2058 produces CLA to ameliorate DSS-induced acute colitis in mice. RSC Advances, 2016, 6, 14457-14464.	1.7	35
39	Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Review of Clinical Immunology, 2016, 12, 741-749.	1.3	3
40	ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2017, 112, 241-258.	0.2	364
41	The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2017, 66, 839-851.	6.1	630
42	Metastatic Epstein-Barr Virus-Positive Lymphoepithelioma-Like Cholangiocarcinoma in a Young Man With Ulcerative Colitis. American Journal of Gastroenterology, 2017, 112, 518-520.	0.2	5
43	What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?. Digestive Diseases, 2017, 35, 50-55.	0.8	10
44	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324
45	Thiopurines in Crohn's Disease. , 2017, , 321-331.		0
46	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Revista De Gastroenterología De México (English Edition), 2017, 82, 134-155.	0.1	2
47	Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives. Journal of Crohn's and Colitis, 2017, 11, 1011-1018.	0.6	42
48	Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). Revista De Gastroenterología De México, 2017, 82, 134-155.	0.4	4
49	Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 515-529.	1.0	14
50	The Usefulness of Serologic Testing for Epstein-Barr Virus Before Initiation of Therapy for Inflammatory Bowel Disease. Gastroenterology, 2017, 153, 1167.	0.6	6
51	Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab. GE Portuguese Journal of Gastroenterology, 2017, 24, 279-284.	0.3	1
52	Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 769-777.	1.4	28
53	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Alimentary Pharmacology and Therapeutics, 2017, 45, 276-282.	1.9	98
55	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. International Journal of Molecular Sciences, 2017, 18, 1276.	1.8	47
56	Healthcare maintenance in elderly patients with inflammatory bowel disease. Annals of Gastroenterology, 2017, 30, 273-286.	0.4	8

#	ARTICLE	IF	CITATIONS
57	Women with inflammatory bowel diseases have a suboptimal cervical cancer screening rate and are not aware of the recommended human papilloma virus vaccine. <i>Gynecological Endocrinology</i> , 2018, 34, 656-658.	0.7	7
58	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. <i>Gastroenterología Y Hepatología (English) Tj ETQq1 1 0.784314 r8BT /Ove</i>	0.7	19
59	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 205-221.	0.2	34
60	Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan. <i>Surgery Today</i> , 2018, 48, 584-590.	0.7	19
61	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	2.3	427
62	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 610-620.	0.6	67
63	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 17-31.	0.6	151
64	Discontinuation of Biological Treatments in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 6-12.	1.1	8
65	Safe use of infliximab for the treatment of severe perianal Crohn's disease after diagnosis and treatment of lymphoma. <i>Clinical Journal of Gastroenterology</i> , 2018, 11, 48-52.	0.4	3
66	Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015. <i>Journal of Clinical Medicine</i> , 2018, 7, 394.	1.0	10
67	Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 9-15.	1.0	1
68	Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2018, 25, 175-178.	0.3	2
69	Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 723-730.	1.9	35
70	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 1558-1570.	2.7	80
71	Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2395-2403.	1.1	22
72	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 450-459.	0.9	33
73	Crohn's Disease and the Risk of Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2019, 32, 305-313.	0.5	8
74	Risks and Side Effects of Medical Therapy. , 2019, , 125-132.		1

#	ARTICLE	IF	CITATIONS
76	The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. <i>Nutrients</i> , 2019, 11, 1019.	1.7	140
77	Evaluation of de-escalation of anti-TNF- α therapy in inflammatory bowel disease. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2019, 42, 133-140.	0.0	0
78	Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 68, 676-683.	0.9	11
79	Atypical Lymphoid Proliferations and Clonality in Helicobacter-associated Inflammatory Infiltrates in Children. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1361-1367.	2.1	2
80	The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 998-1005.	0.9	13
81	Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience. <i>Digestive Diseases and Sciences</i> , 2019, 64, 875-879.	1.1	8
82	Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 807-811.	0.6	11
83	EvaluaciÃ3n del retiro progresivo y/o la suspensiÃ3n de la terapia anti-TNF- α en la enfermedad inflamatoria intestinal. <i>GastroenterologÃa Y HepatologÃa</i> , 2019, 42, 133-140.	0.2	0
84	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factorsâ€”Results from the Swiss IBD Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 116-126.	0.2	39
85	Unusual intestinal and extra intestinal findings in Crohn's disease seen on abdominal computed tomography and magnetic resonance enterography. <i>Clinical Imaging</i> , 2020, 59, 30-38.	0.8	4
86	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 192-204.	0.6	45
87	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 617-623.	0.6	26
88	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 628-636.	2.4	12
89	Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3250-3262.	1.1	5
90	Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications. <i>American Journal of Gastroenterology</i> , 2020, 115, 1246-1252.	0.2	11
91	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	1.9	97
92	Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism. <i>Journal of Nutritional Biochemistry</i> , 2020, 79, 108353.	1.9	66
93	The Complex Interplay Between Inflammatory Bowel Disease and Malignancy. <i>Current Gastroenterology Reports</i> , 2020, 22, 13.	1.1	10

#	ARTICLE	IF	CITATIONS
94	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. <i>Techniques in Coloproctology</i> , 2020, 24, 105-126.	0.8	31
95	Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1464-1473.	0.6	10
96	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 234-245.	0.9	11
97	Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 183-191.	0.9	7
98	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	2.3	202
99	Dietary Management in Pediatric Patients with Crohn's Disease. <i>Nutrients</i> , 2021, 13, 1611.	1.7	15
100	Crohn's disease exclusion diet in children with Crohn's disease: a case series. <i>Current Medical Research and Opinion</i> , 2021, 37, 1115-1120.	0.9	10
101	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016, 29, 127-36.	0.4	8
102	Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	26
103	Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. <i>World Journal of Gastroenterology</i> , 2013, 19, 6375.	1.4	8
104	Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 9359.	1.4	30
105	Positioning of old and new biologics and small molecules in the treatment of inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2018, 24, 3567-3582.	1.4	34
106	Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. <i>World Journal of Gastroenterology</i> , 2019, 25, 4158-4171.	1.4	28
107	Use of thiopurines in inflammatory bowel disease: Safety issues. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 63.	0.6	49
108	How I treat my inflammatory bowel disease-patients with thiopurines?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 524.	0.6	8
109	Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. <i>Gut and Liver</i> , 2018, 12, 623-632.	1.4	11
110	The Risk of Hepatosplenic T-Cell Lymphoma (HSTCL) in Women with Inflammatory Bowel Disease (IBD) on Thiopurines. <i>Journal of Inflammatory Bowel Diseases & Disorders</i> , 2016, 01, .	0.1	0
111	EFFICACY AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE (review). <i>Koloproktologia</i> , 2017, , 71-79.	0.1	0

#	ARTICLE	IF	CITATIONS
112	Health Maintenance for Adult Patients with Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2021, 19, 583-596.	0.3	5
113	Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Alimentary Pharmacology and Therapeutics, 2021, , .	1.9	3
114	Solid extraintestinal malignancies in patients with inflammatory bowel disease. World Journal of Gastrointestinal Oncology, 2021, 13, 1956-1980.	0.8	5
115	Risk of cervical cancer in inflammatory bowel disease: A meta-analysis of population-based studies. Clinical and Translational Gastroenterology, 2022, Publish Ahead of Print, .	1.3	5
116	Discontinuation of Infliximab Therapy in Patients with Crohn's Disease. , 2022, 1, .		17
117	Risk of prostate cancer in patients with inflammatory bowel disease: a nationwide cohort study in South Korea. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211374.	1.4	4
118	ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2023, 17, 827-854.	0.6	36
119	Risiken und Nebenwirkungen der medikamentösen Therapie. , 2023, , 165-174.		0
120	The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer. Journal of Clinical Medicine, 2023, 12, 2432.	1.0	3